Longeveron (LGVN) News Today $1.79 +0.06 (+3.47%) (As of 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Longeveron (NASDAQ:LGVN) Trading Up 1.1% - Should You Buy?December 31 at 2:51 AM | americanbankingnews.comLongeveron to Present at Biotech Showcase 2025December 18, 2024 | globenewswire.comRoth MKM Initiates Coverage of Longeveron (LGVN) with Buy RecommendationDecember 6, 2024 | msn.comLongeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024December 2, 2024 | globenewswire.comLongeveron Buy Rating Affirmed: Promising Clinical Developments and Strong Financial PositionNovember 26, 2024 | markets.businessinsider.comLongeveron Inc. (LGVN) Latest Stock News & Headlines - Yahoo FinanceNovember 24, 2024 | finance.yahoo.comLGVN Highlights Potential Groundbreaking TreatmentsNovember 13, 2024 | msn.comA Look Ahead: Longeveron's Earnings ForecastNovember 13, 2024 | benzinga.comLongeveron® Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finance.yahoo.comLongeveron, Inc. (LGVN) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comEarnings To Watch: Longeveron Inc (LGVN) Reports Q3 2024 ResultNovember 11, 2024 | finance.yahoo.comLongeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)November 11, 2024 | globenewswire.comPromising Prospects for Lomecel-B: A Buy Recommendation Based on Positive Clinical Data and Regulatory PotentialNovember 5, 2024 | markets.businessinsider.comLongeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024November 4, 2024 | globenewswire.comLongeveron presents Alzheimer's therapy data at CTAD24October 31, 2024 | investing.comLongeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)October 29, 2024 | globenewswire.comLongeveron presents Lomecel-B long-term transplant-free survival data in HLHSOctober 29, 2024 | markets.businessinsider.comLGVN Announces Treatment Garners Excellent ResultsOctober 29, 2024 | msn.comLongeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual MeetingOctober 27, 2024 | globenewswire.comLongeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)October 14, 2024 | globenewswire.comLongeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual MeetingOctober 9, 2024 | globenewswire.comLongeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy DayOctober 7, 2024 | globenewswire.comLongeveron (NASDAQ:LGVN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comLongeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comBioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the MesaSeptember 27, 2024 | msn.comLongeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the MesaSeptember 26, 2024 | finance.yahoo.comLongeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the MesaSeptember 26, 2024 | globenewswire.comBuy Rating Affirmed for Longeveron on Favorable Lomecel-B Regulatory Outlook and Trial ProgressSeptember 4, 2024 | markets.businessinsider.comLongeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)September 3, 2024 | msn.comBioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Alignment with FDA on Development Pathway for Lomecel-B(TM) in HLHSSeptember 3, 2024 | msn.comLongeveron to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 26, 2024 | globenewswire.comBuy Rating Reaffirmed for Longeveron on Strong Clinical Trial Prospects and Regulatory AdvantagesAugust 15, 2024 | markets.businessinsider.comLongeveron, Inc. (LGVN) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comLGVN Solidifies Financials so Treatment Can AdvanceAugust 15, 2024 | msn.comThe Top 3 Small-Cap Stocks to Buy Now: Summer 2024August 1, 2024 | investorplace.comLongeveron (LGVN) Stock Pops on Phase 2 Trial UpdatesJuly 29, 2024 | investorplace.comLongeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)July 28, 2024 | globenewswire.comBullish Longeveron Insiders Loaded Up On US$734.3k Of StockJuly 27, 2024 | finance.yahoo.comLongeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 19, 2024 | globenewswire.comLongeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 18, 2024 | globenewswire.comLongeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 18, 2024 | globenewswire.comLGVN Stock Alert: Longeveron Pops 18% on FDA Fast-Track DesignationJuly 17, 2024 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 53% Today?July 10, 2024 | investorplace.comLongeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's DiseaseJuly 10, 2024 | globenewswire.comNeha Motwani Elected to Longeveron® Board of DirectorsJuly 9, 2024 | globenewswire.comGene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of DirectorsJuly 8, 2024 | globenewswire.com3 Penny Stocks Poised to Turn Pocket Change Into a Small Fortune by 2028June 19, 2024 | investorplace.comLongeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise TransactionJune 18, 2024 | globenewswire.comLongeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024June 17, 2024 | globenewswire.comLongeveron Announces Exercise of Warrants for $4.4 Million Gross ProceedsJune 17, 2024 | globenewswire.com Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price. Click here for the ticker >>> LGVN Media Mentions By Week LGVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGVN News Sentiment▼0.000.65▲Average Medical News Sentiment LGVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGVN Articles This Week▼11▲LGVN Articles Average Week Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRDL News MNOV News INMB News CLLS News OSTX News NVCT News EDIT News ADVM News COYA News APLT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGVN) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Next Big Thing in AI: Musk’s Secret SupplierWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
